Lambert-Eaton Myasthenic Syndrome (LEMS) is a relatively rare disease of the neuromuscular junction, which typically represents progressive, symmetric, proximal muscle weakness, usually in the lower extremities. Patients frequently face difficulty in walking, climbing steps, or arising from a seated position. Rarely patients also suffer from isolated facial weakness (most commonly ptosis), or respiratory failure. Autonomic complaints such as the dry mouth or erectile dysfunction are common.
LEMS is characterized by weakness and fatigue, especially of the muscles in the legs and arms. It can affect many muscles, but mostly, it causes weakness commonly in the upper legs and hips more than the upper arms and shoulders. These proximal muscles are more likely to get tired with use, and muscle fatigue and sometimes stiffness may be more common than actual weakness. The legs are significantly affected. There may be a problem getting out of a chair, going upstairs, running, or walking. Lifting and pushing may be strenuous.
Lambert-Eaton Myasthenic Syndrome Epidemiological Segmentation
The Epidemiological Segmentation of Lambert-Eaton Myasthenic Syndrome in 7MM from 2017 to 2030 is segmented as:-
- Total Prevalent Cases
- Total Diagnosed Prevalence
- Gender-specific Diagnosed Prevalence
- Type-specific Diagnosed Prevalence
- Diagnosed Prevalent Cases by Malignancy
Lambert-Eaton Myasthenic Syndrome Epidemiology
- The total prevalent population of LEMS in the 7MM in 2017 was 5,977
- The prevalence of LEMS in the United States was 3,255
The therapeutic market of LEMS in 7MM in 2017 was USD 59.43 million
Lambert-Eaton Myasthenic Syndrome Market Drivers
- Development of a New Diagnostic Approach
- Increased Awareness
- Improved clinical recognition of LEMS
Lambert-Eaton Myasthenic Syndrome Market Barriers
- Limited Clinical trials
- Lack of Disease Understanding
Lambert-Eaton Myasthenic Syndrome Marketed Drugs
The Marketed drugs of the Lambert-Eaton Myasthenic Syndrome market are
And many others.
Lambert-Eaton Myasthenic Syndrome Key Players
The key players in the Lambert-Eaton Myasthenic Syndrome market are
- Catalyst Pharmaceutical
- Jacobus Pharmaceutical
And many others.